Entecavir Tablets IP 0.5 Mg - ENTORYL 0.5 Tablets

ENTORYL 0.5 Tablets
Composition: Entecavir Tablets IP 0.5 mg

ENTORYL 0.5 Tablets – Entecavir Tablets IP 0.5 mg contain Entecavir, a potent guanosine nucleoside analogue widely regarded as a first-choice treatment for chronic hepatitis B. By significantly reducing HBV DNA load and improving liver histology, it helps protect liver function and prevent disease progression. With its high genetic barrier to resistance, durable antiviral activity, and favorable safety profile, Entecavir is recognized as a Gold-Standard Antiviral for Chronic Hepatitis B in HBV management.

Key Point of Entecavir 0.5 mg Tablets – ENTORYL 0.5 Tablets:
✅Robust Resistance Barrier – Ensures sustained viral suppression with very low mutation potential, making it suitable for prolonged HBV therapy.
✅Powerful Antiviral Efficacy – Effectively blocks all three key actions of HBV polymerase: priming, reverse transcription, and DNA synthesis.
✅Reliable Safety & Tolerability – Demonstrates minimal renal or bone-related adverse effects, with convenient once-daily dosing to enhance compliance.

Can be Prescribed by:
👨‍⚕️  Hepatologists 
👨‍⚕️ Gastroenterologists
👨‍⚕️ General Physicians 
👨‍⚕️ Healthcare practitioner

📢 Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.